Reply to: “Improving the Reporting of Long-Term Effects in the IMpower010 Trial” and “Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity”

Enriqueta Felip

Medical Oncology Service, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona

Heather A. Wakelee

Chenqi Fu

Yu Deng

Fanny Masson

Enriqueta Felip, MD, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA; Chenqi Fu, PhD, and Yu Deng, PhD, Genentech Inc, South San Francisco, CA; Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA

Barbara Gitlitz

Enriqueta Felip, MD, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Heather A. Wakelee, MD, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA; Chenqi Fu, PhD, and Yu Deng, PhD, Genentech Inc, South San Francisco, CA; Fanny Masson, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and Barbara Gitlitz, MD, Genentech Inc, South San Francisco, CA